Text version
Greetings! This is David Rosenberg from the Psychopharmacology Institute. In this CAP—or Child and Adolescent Psychiatry—Smart Take, we will focus on a crucial area: The use of esketamine in adolescents suffering from major depressive disorder and suicidal ideation. This topic bears significance due to the widespread interest in ketamine’s powerful, swift effects on adults with depression and suicidal ideation—effects that significantly surpass those of traditional antidepressant treatments, which may require several weeks to manifest. The need for alternate treatment options for adolescent major depressive disorder makes this an intriguing area of study.
Lan and colleagues investigated the short-term cognitive impacts of repeated doses of esketamine in adolescents diagnosed with major depressive disorder and suicidal ideation. One notable aspect of their study was its randomized controlled design, involving 51 participants aged 13–18 who received 3 intravenous infusions of either esketamine (0.25 mg/kg) or midazolam (0.02 mg/kg). The study’s findings were quite
Unlock this CAP Smart Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.
Already have an account? Sign in
